治疗角膜新生血管抗血管内皮生长因子药物的选择

摘要

The studies and clinical applications of Ranibizumab and Bevacizumab which are new anti-VEGF drugs have made significant progression on the treatment of corneal neovascularization.The effectiveness and safety of Ranibizumab compared with Bevacizumab has been the focus of the debate for scholars nowadays.Some experiments showed that the effect of Bevacizumab was better than Ranibizumab.But combined with our experiments, Ranibizumab represented the advantages of shorter effect time, stronger affinity with VEGF-A, better tolerance with repeated injections etc.So we believed that the adequate doses of ranibizumab had better effects.Its clinical application should be paid much attention.%在治疗角膜新生血管方面,以雷珠单抗和贝伐单抗为代表的新型抗VEGF药物的临床应用及研究均取得重大突破,而二者的有效性及安全性比较是当前临床争议的焦点.虽然部分实验结果表明贝伐单抗的药效优于雷珠单抗,但是雷珠单抗具有起效时间短、对VEGF-A的亲和力强、重复注射时耐受性好等优点.结合实验研究结果,我们认为充足剂量的雷珠单抗效果更优,其临床应用应引起广泛重视.